γ-Diketone central neuropathy: Quantitative morphometric analysis of axons in rat spinal cord white matter regions and nerve roots

Toxicology and Applied Pharmacology

Volumn 193, Issue 1, 2003, Pages 29-46

  LoPachin, Richard M ^a,c   Jortner, Bernard S ^b   Reid, Maria L ^a   Das, Soma ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

2,5 Hexanedione; Axon atrophy; Axon swellings; Distal axonopathy; Diketone neuropathy

Indexed keywords

1,4 DIKETONE; ACETONYLACETONE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GAIT; GRIP STRENGTH; MALE; MORPHOMETRICS; MYELINATED NERVE; NERVE FIBER DEGENERATION; NERVE ROOT; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; RAT; WHITE MATTER;

EID: 0242677820     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.07.005     Document Type: Article

References (73)

1. Anderson R.J., Dunham C.B. Electrophysiological deficits in peripheral nerve as a discriminator of early hexacarbon neurotoxicity. J. Toxicol. Environ. Health. 13:1984;835-843.
2. Anthony D.C., Boekelheide K., Graham D.G. The effect of 3,4-dimethyl substitution on the neurotoxicity of 2,5-hexanedione. I. Accelerated clinical neuropathy is accompanied by more proximal axonal swellings. Toxicol. Appl. Pharmacol. 71:1983;362-371.
3. Anthony D.C., Giangaspero F., Graham D.G. The spatio-temporal pattern of the axonopathy associated with the neurotoxicity of 3,4-dimethyl-2, 5-hexanedione in the rat. J. Neuropathol. Exp. Neurol. 42:1983;548-560.
4. Barber D.S., Hunt J.R., Ehrich M.F., Lehning E.J., LoPachin R.M. Metabolism, toxicokinetics and hemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing. Neuro toxicology. 22:2001;341-353.
5. Brown M.J., DeJesus P.V., Pleasure D.E., Asbury A.K. Nerve conduction slowing precedes demyelination in experimental n-butyl ketone (MBK) neuropathy. Aguayo A., Kanpati G. Proceedings of the IVth International Congress on Neuromuscular Disease. 1978;276-301 Excerpta Medica, Amsterdam.
6. Burek J.D., Albee R.R., Beyer J.E., Bell T.J., Carreon R.M., Morden D.C., Wade C.E., Hermann E.A., Gorzinski S.J. Subchronic toxicity of acrylamide administered to rats in drinking water followed by up to 144 days of recovery. J. Environ. Pathol. Toxicol. 4:1980;157-182.
7. Carden M.J., Lee V.M.-Y., Schalepfer W.W. 2,5-Hexanedione neuropathy is associated with the covalent crosslinking of neurofilament proteins. Neurochem. Pathol. 5:1986;25-35.
8. Chiu F.C., Opanashuk L.A., He D.K., Lehning E.J., LoPachin R.M. γ-Diketone peripheral neuropathy. II. Neurofilament subunit content. Toxicol. Appl. Pharmacol. 165:2000;141-147.
9. DeCaprio A.P. Molecular mechanisms of diketone neurotoxicity. Chem-Biol. Interact. 54:1985;257-270.
10. DeCaprio A.P. n-Hexane neurotoxicity a mechanism involving pyrrole adduct formation in axonal cytoskeletal protein . Neurotoxicology. 8:1987;199-210.
11. DeCaprio A.P., Briggs R.G., Jackowski S.J., Kim J.C.S. Comparative neurotoxicity and pyrrole-forming potential of 2,5-hexanedione and perdeuterio-2,5-hexanedione in the rat. Tox. Appl. Pharmacol. 92:1988;75-85.
12. DeCaprio A.P., Kinney E.A., Fowke J.H. Regioselective binding of 2,5-hexanedione to high-molecular-weight rat neurofilament proteins in vitro. Toxicol. Appl. Pharmacol. 145:1997;211-217.
13. DeCaprio A.P., O'Neil E.A. Alterations in rat axonal cytoskeletal proteins induced by in vitro and in vivo 2,5-hexanedione exposure. Toxicol. Appl. Pharmacol. 78:1985;235-247.
14. DeCaprio A.P., Strominger N.L., Weber P. Neurotoxicity and protein binding og 2,5 hexanedione in the hen. Tox. Appl. Pharm. 68:1983;297-307.
15. Fraher J.P. A quantitative study of anterior root fibres during early myelination. J. Anat. 112:1972;99-124.
16. Genter St. Clair M.B., Amarnath V., Moody M.A., Anthony D.C., Anderson C.W., Graham D.G. Pyrrole oxidation and protein cross-linking as necessary steps in the development of γ-diketone neuropathy. Chem. Res. Toxicol. 1:1988;179-185.
17. Gill J.L. Design and Analysis of Experiments in the Animal and Medical Sciences. 1978;Iowa State University Press, Ames, IA.
18. Gillespie M.J., Stein R.B. The relationship between axon diameter, myelin thickness and conduction velocity during atrophy of mammalian peripheral nerves. Brain Res. 259:1983;41-56.
19. Glass J.D., Griffin J.W. Neurofilament redistribution in transected nerves evidence for bi-directional transport of neurofilaments . J. Neurosci. 11:1991;3154-3164.
20. Graham D.G., Anthony D.C., Boekelheide K., Maschmann N.A., Richards R.G., Wolfram J.W., Shaw B.R. Studies of the molecular pathogenesis of hexane neuropathy.II. Evidence that pyrrole derivitization of lysyl residues leads to protein crosslinking. Tox. Appl. Pharm. 64:1982;415-422.
21. Graham D.G., Amarnath V., Valentine W.M., Pyle S.J., Anthony D.C. Pathogenetic studies of hexane and carbon disulfide neurotoxicity. Crit. Rev. Toxicol. 25:1995;91-112.
22. Horan K.I., Eichberg J., Berti-Mattera L.N., LoPachin R.M. Hexanedione effects on protein phosphorylation in rat peripheral nerve. Brain Res. 491:1989;366-370.
23. Jones H.B., Cavanagh J.B. The early evolution of neurofilamentous accumulations due to 2,5-hexanediol in the optic pathways of the rat. Neuropathol. Appl. Neurobiol. 8:1982;289-301.
24. Jones H.B., Cavanagh J.B. Distortions of the nodes of Ranvier form axonal distension by filamentous masses in hexacarbon intoxication. J. Neurocytol. 12:1983;439-458.
25. Karlsson J.-E., Rosengren L.E., Haglid K.G. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. J. Neurochem. 57:1991;1437-1444.
26. Krasavage W.J., O'Donoghue J.L., DiVincenzo G.D., Terhaar C.J. The relative neurotoxicity of methyl n-butyl ketone, n-hexane and their metabolites. Toxicol. Appl. Pharmacol. 52:1980;433-441.
27. Lapadula D.M., Irwin R.D., Suwita E., Abou-Donia M.B. Cross-linking of neurofilament proteins of rat spinal cord in vivo after administration of 2,5-hexanedione. J. Neurochem. 46:1986;1843-1850.
28. Lapadula D.M., Suwita E., Abou-Donia M.B. Evidence for multiple mechanisms responsible for 2,5-hexanedion-induced neuropathy. Brain Res. 458:1988;123-131.
29. Lee M.K., Cleveland D.W. Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease. Curr. Opin. Cell Biol. 6:1994;34-40.
30. Lehning E.J., Dyer K.S., Jortner B.S., LoPachin R.M. Axonal atrophy is a specific component of 2,5-hexanedione peripheral neuropathy. Toxicol. Appl. Pharmacol. 135:1995;58-66.
31. Lehning E.J., Jortner B.S., Fox J.H., Arezzo J.C., Kitano T., LoPachin R.M. γ-Diketone peripheral neuropathy. I. Quantitative morphometric analyses of axonal atrophy and swelling. Toxicol. Appl. Pharmacol. 165:2000;127-140.
32. Lehning E.J., Persaud A., Dyer K.S., Jortner B.S., LoPachin R.M. Biochemical and morphological characterization of acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 151:1998;211-221.
33. Lewis S.E., Nixon R.A. Multiple phosphorylated variants of the high molecular mass subunit of neurofilaments in axons of retinal cell neurons characterization and evidence for their differential association with stationary and moving neurofilaments . J. Cell Biol. 107:1988;2689-2701.
34. LoPachin R.M., Balaban C.D., Ross J.F. Acrylamide axonopathy revisited. Toxicol. Appl. Pharmacol. 188:2003;135-153.
35. LoPachin, R.M., He, D.K. 2003. γ-Diketone central neuropathy: molecular mechanisms of axon atrophy. Toxicol. Appl. Pharmacol. Submitted for publication.
36. LoPachin R.M., Lehning E.J. The relevance of axonal swelling and atrophy to γ-diketone neurotoxicity. Neurotoxicology. 18:1997;7-22.
37. LoPachin R.M., Lehning E.J. Mechanism of calcium entry during axon injury and degeneration. Toxicol. Appl. Pharmacol. 143:1997;233-244.
38. LoPachin R.M., Lehning E.J., Opanashuk L.A., Jortner B.S. Rate of neurotoxicant exposure determines morphological manifestations. Toxicol. Appl. Pharmacol. 167:2000;75-86.
39. LoPachin R.M., Lehning E.J., Stack E.C., Hussein S.J., Saubermann A.J. 2,5-Hexanedione alters elemental composition and water content of rat peripheral nerve myelinated axons. J. Neurochem. 63:1994;2266-2278.
40. LoPachin R.M., Ross J.F., Lehning E.J. Nerve terminals as the primary site of acrylamide action a hypothesis . Neurotoxicology. 23:2002;43-59.
41. LoPachin R.M., Ross J.F., Reid M.L., Das S., Mansukhani S., Lehning E.J. Neurological evaluation of toxic axonopathies in rats acrylamide and 2,5-hexanedione . Neurotoxicology. 23:2002;95-110.
42. Manetto V., Perry G., Tabaton M., Mulvihill P., Fried V.A., Smith H.T., Gambetti P., Autilio-Gambetti L. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 85:1988;4501-4505.
43. Maxwell W.L., Povlishock J.T., Graham D.L. A mechanistic analysis of nondisruptive axonal injury a review . J. Neurotrauma. 14:1997;419-440.
44. Monaco S., Autilio-Gambetti L., Lasek R.J., Katz M.J., Gambetti P. Experimental increase of neurofilament transport rate decreases in neurofilament number and in axon diameter . J. Neuropathol. Exp. Neurol. 48:1989;23-32.
45. Monaco S., Autilio-Gambetti L., Zabel D., Gambetti P. Giant axonal neuropathy acceleration of neurofilament transport in optic axons . Proc. Natl. Acad. Sci. USA. 82:1985;920-924.
46. Monaco S., Jacob J., Jenich H., Autilio-Gambetti L., Gambetti P. Axonal transport of neurofilament is accelerated in peripheral nerve during 2,5-hexanedione intoxication. Brain Res. 491:1989;328-334.
47. Monaco S., Simonati A., Rizzuto N., Autilio-Gambetti L., Gambetti P. Hexacarbon axonopathy the morphological expression of altered cytoskeletal translocation . Nappi G. Neurodegenerative Disorders The Role Played by Endotoxins and Xenobiotics . 1988;239-251 Raven Press, NewYork.
48. Monaco S., Wongmongkolrit T., Shearson C.M., Patton A., Schaetzle B., Autilio-Gambetti L., Gambetti P., Sayre L.M. Giant axonopathy characterized by intermediate location of axonal enlargements and acceleration of neurofilament transport. Brain Res. 519:1990;73-81.
49. Moretto G., Monaco S., Passarin M.G., Benedetti M.D., Rizzuto N. Cytoskeletal changes induced by 2,5-hexanedione on developing human neurons in vitro. Arch. Toxicol. 65:1991;409-413.
50. Muma N.A., Hoffman P.N. Neurofilaments are intrinsic determinants of axonal caliber. Micron. 24:1993;677-683.
51. Nachtman J.P., Couri D. Biophysical and electrophysiological studies of hexanedione neurotoxicity. Neurotoxicology. 2:1981;541-556.
52. Nixon R.A., Paskevich P.A., Sihag R.K., Thayer C.Y. Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo influences on regional neurofilament accumulation, interneurofilament spacing and axon caliber . J. Cell Biol. 126:1994;1031-1046.
53. Ochs S., Pourmand R., Jersild R.A., Friedman R.N. The origin and nature of beading a reversible transformation of the shape of nerve fibers . Prog. Neurobiol. 52:1997;391-426.
54. Ogawa Y., Komatsu T., Fujikake N., Fujii T., Tanaka J. Neurotoxic effects of 2,5-hexanedione on rapidly growing unmyelinated peripheral nerve axons of a rat fetus dose-effect relationship . Environ. Res. 63:1993;287-295.
55. Opanashuk L.A., He D.K., Lehning E.J., LoPachin R.M. γ-Diketone peripheral neuropathy. III. Neurofilament gene expression. Neurotoxicology. 22:2001;215-220.
56. O'Shaughnessy D.J., Losos G.J. Comparison of central and peripheral nervous system lesions caused by high-dose short-term and low-dose subchronic acrylamide treatment in rats. Toxicol. Pathol. 14:1986;389-394.
57. Pyle S.J., Amarnath V., Graham D.G., Anthony D.C. Alterations in neurofilament transport induced by 2,5-hexanedione and 3-acetyl-2,5-hexanedione. J. Neuropathol. Exp. Neurol. 51:1992;451-458.
58. Pyle S.J., Amarnath V., Graham D.G., Anthony D.C. Decreased levels of the high molecular weight subunit of neurofilaments and accelerated neurofilament transport during the recovery phase of 2,5-hexanedione. Cell Motil. Cytoskel. 26:1993;133-143.
59. Rosenberg C.K., Genter M.B., Szakal-Quin G., Anthony D.C., Graham D.G. D,L-versus meso-3,4-dimethyl-2,5-hexanedione a morphometric study of the proximo-distal distribution of axonal swellings in the anterior root of the rat . Toxicol. Appl. Pharmacol. 87:1987;363-373.
60. Sakaguchi T., Okada M., Kitamura T., Kawasaki K. Reduced diameter and conduction velocity of myelinated fibers in the sciatic nerve of a neurofilament-deficient mutant quail. Neurosci. Lett. 153:1993;65-68.
61. Schaumburg H.H., Spencer P.S. Degeneration in central and peripheral nervous systems produced by pure n-hexane an experimental study . Brain. 99:1976;183-192.
62. Shea T.B. Microtubule motors, phosphorylation and axonal transport of neurofilaments. J. Neurocytol. 29:2000;873-887.
63. Smith D.H., Wolf J.A., Lusardi T.A., Lee V.M.-Y., Meaney D.F. High tolerance and delayed elastic response of cultured axons to dynamic stretch injury. J. Neurosci. 19:1999;4263-4269.
64. Spencer P.S., Schaumburg H.H. Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J. Neuropathol. Exp. Neurol. 36:1977;276-299.
65. Spencer P.S., Schaumburg H.H. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies. J. Neuropathol. Exp. Neurol. 36:1977;300-319.
66. Spencer P.S., Couri D., Schaumburg H.H. n-Hexane and methyl n-butyl ketone. Spencer P.S., Schaumburg H.H. Experimental and Clinical Neurotoxicology. 1980;456-475 Williams and Wilkins, Baltimore.
67. Spencer P.S., Schaumburg H.H., Sabri M.I., Veronesi B. The enlarging view of hexacarbon neurotoxicity. CRC Crit. Rev. Toxicol. 7:1980;279-356.
68. Terada M., Yasuda H., Kikkawa R., Koyanma N., Yokota T., Shigeta Y. Electrophysiological study of dorsal column function in streptozotocin-induced diabetic rats comparison with 2,5-hexanedione intoxication . J. Neurol. Sci. 115:1993;58-66.
69. Tuckwell D.S., Laszlo L., Mayer R.J. 2,5-Hexanedione-induced intermediate filament aggregates contain ubiquitin-protein conjugate immunoreactivity and resemble Rosenthal fibres. Neuropathol. Appl. Neurobiol. 18:1992;593-609.
70. Watson D.F., Fittro K.P., Hoffman P.N., Griffin J.W. Phosphorylation- related immunoreactivity and the rate of transport of neurofilaments in chronic 2,5-hexanedione intoxication. Brain Res. 539:1991;103-109.
71. Yagi Y. Effects of 2,5-hexanedione on rat spinal pyramidal tract. Jpn. J. Ind. Health. 36:1994;173-180.
72. Yoshimura S., Imai K., Saitoh Y., Yamaguchi H., Ohtaki S. The same chemicals induce different neurotoxicity when administered in high doses for short term or low doses for long term to rats and dogs. Mol. Chem. Neuropathol. 16:1992;59-83.
73. Zhu M., Spink D.C., Yan B., Bank S., DeCaprio A.P. Formation and structure of cross-linking and monomeric pyrrole autooxidation products in 2,5-hexanedione-treated amino acids, peptides and proteins. Chem. Res. Toxicol. 7:1994;551-558.